Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/57053
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
Metadatos
Mostrar el registro completo del ítem
GENE THERAPY ACCESS: GLOBAL CHALLENGES, OPPORTUNITIES, AND VIEWS FROM BRAZIL, SOUTH AFRICA, AND INDIA
Global challenges
Cell therapies
Cancer deaths
Gene therapy clinical
Autor
Afiliación
Department of Medical and Molecular Genetics. Indiana University School of Medicine. Indianapolis, USA.
Molecular Carcinogenesis Program, Research, Coordination National Cancer Institute. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Presidency. Vice-Presidency Research and Biological Collections. Rio de Janeiro, RJ, Brazil.
Department of Molecular Medicine and Haematology. School of Pathology. Faculty of Health Sciences. University of the Witwatersrand. Johannesburg, South Africa.
Spark Therapeutics. Philadelphia, USA.
Faculty of Medicine. University of Southampton. UK & KJ Somaiya. Super Speciality Hospital and Research Centre. Mumbai, India.
Department of Biological Sciences and Bioengineering. Indian Institute of Technology Kanpur. Kapur, India.
Molecular Carcinogenesis Program, Research, Coordination National Cancer Institute. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Presidency. Vice-Presidency Research and Biological Collections. Rio de Janeiro, RJ, Brazil.
Department of Molecular Medicine and Haematology. School of Pathology. Faculty of Health Sciences. University of the Witwatersrand. Johannesburg, South Africa.
Spark Therapeutics. Philadelphia, USA.
Faculty of Medicine. University of Southampton. UK & KJ Somaiya. Super Speciality Hospital and Research Centre. Mumbai, India.
Department of Biological Sciences and Bioengineering. Indian Institute of Technology Kanpur. Kapur, India.
Resumen en ingles
Gene and cell therapies for a variety of life-limiting illnesses are under investigation, and a small number of commercial products have successfully obtained regulatory approval. The cost of treatment is high, and clinical studies evaluating safety and efficacy are performed predominately in high-income countries. We reviewed the current status of gene and cell therapies in low- and middle-income countries and highlighted the need and current barriers to access. The state of product development in Brazil, South Africa, and India is discussed, including lessons learned from American Society of Gene and Cell Therapy (ASGCT)-sponsored virtual symposia in each of these countries.
Palabras clave en ingles
Gene therapy accessGlobal challenges
Cell therapies
Cancer deaths
Gene therapy clinical
Compartir